Eyenovia Ownership
| EYEN Stock | USD 1.71 0.06 3.64% |
Eyenovia |
Eyenovia Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.93. Some equities with similar Price to Book (P/B) outperform the market in the long run. Eyenovia recorded a loss per share of 55.2. The entity had not issued any dividends in recent years. The firm had 1:80 split on the 3rd of February 2025. Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York. Eyenovia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 43 people. To learn more about Eyenovia call Michael Rowe at 833 393 6684 or check out https://www.eyenovia.com.Besides selling stocks to institutional investors, Eyenovia also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Eyenovia's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Eyenovia's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Eyenovia Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Eyenovia are currently held by insiders. Unlike Eyenovia's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Eyenovia's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Eyenovia's insider trades
Eyenovia Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eyenovia is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eyenovia backward and forwards among themselves. Eyenovia's institutional investor refers to the entity that pools money to purchase Eyenovia's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jane Street Group Llc | 2024-09-30 | 38.2 K | Callan Capital, Llc | 2024-12-31 | 30 K | Susquehanna International Group, Llp | 2024-09-30 | 29.9 K | Point72 Asia (singapore) Pte. Ltd | 2024-09-30 | 23.3 K | Mariner Wealth Advisors Llc | 2024-09-30 | 21.7 K | Qube Research & Technologies | 2024-09-30 | 19.5 K | Soltis Investment Advisors, Llc | 2024-12-31 | 18.2 K | Leo Wealth, Llc. | 2024-12-31 | 16.1 K | Cresset Asset Management, Llc | 2024-09-30 | 12.5 K | Geode Capital Management, Llc | 2024-09-30 | 558 K | Lasry Marc | 2024-09-30 | 547.8 K |
Eyenovia Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eyenovia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eyenovia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eyenovia insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eyenovia Outstanding Bonds
Eyenovia issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Eyenovia uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Eyenovia bonds can be classified according to their maturity, which is the date when Eyenovia has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US302301AE67 Corp BondUS302301AE67 | View | |
| EXXON MOBIL P Corp BondUS30231GAN25 | View | |
| EXXON MOBIL P Corp BondUS30231GAF90 | View | |
| EXXON MOBIL P Corp BondUS30231GBK76 | View | |
| EXXON MOBIL P Corp BondUS30231GBN16 | View | |
| EXXON MOBIL P Corp BondUS30231GBM33 | View | |
| EXXON MOBIL P Corp BondUS30231GBG64 | View | |
| EXXON MOBIL P Corp BondUS30231GBF81 | View |
Pair Trading with Eyenovia
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eyenovia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will appreciate offsetting losses from the drop in the long position's value.Moving together with Eyenovia Stock
Moving against Eyenovia Stock
| 0.83 | VALN | Valneva SE ADR Earnings Call Tomorrow | PairCorr |
| 0.78 | VIGL | Vigil Neuroscience | PairCorr |
| 0.69 | DMAC | DiaMedica Therapeutics Earnings Call Today | PairCorr |
| 0.57 | DVAX | Dynavax Technologies | PairCorr |
| 0.56 | SRZNW | Surrozen Warrant | PairCorr |
The ability to find closely correlated positions to Eyenovia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eyenovia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eyenovia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eyenovia to buy it.
The correlation of Eyenovia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eyenovia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eyenovia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eyenovia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (55.20) | Revenue Per Share | Quarterly Revenue Growth 0.356 | Return On Assets | Return On Equity |
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.